Definition of Cataplexy: Cataplexy is a sudden loss of muscle tone, sometimes associated with narcolepsy.
The following drugs and medications are in some way related to, or used in the treatment of Cataplexy. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Finastid may be available in the countries listed below.
Finasteride is reported as an ingredient of Finastid in the following countries:
International Drug Name Search
Dantrolène may be available in the countries listed below.
Dantrolène (DCF) is known as Dantrolene in the US.
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
Mannit Fresenius may be available in the countries listed below.
Mannitol is reported as an ingredient of Mannit Fresenius in the following countries:
International Drug Name Search
Morantel Citrate may be available in the countries listed below.
Morantel Citrate (BANM) is also known as Morantel (Prop.INN)
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| Prop.INN | Proposed International Nonproprietary Name (World Health Organization) |
Tifol may be available in the countries listed below.
Folic Acid sodium salt (a derivative of Folic Acid) is reported as an ingredient of Tifol in the following countries:
International Drug Name Search
Mébévérine Zydus may be available in the countries listed below.
Mebeverine hydrochloride (a derivative of Mebeverine) is reported as an ingredient of Mébévérine Zydus in the following countries:
International Drug Name Search
Kapril may be available in the countries listed below.
Captopril is reported as an ingredient of Kapril in the following countries:
International Drug Name Search
Generic Name: belimumab (be LIM ue mab)
Brand Names: Benlysta
Belimumab is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.
Belimumab is used in to treat active systemic lupus erythematosus (SLE) in adults.
Belimumab is not for use in people who have severe kidney problems caused by SLE, or have active SLE that affects the central nervous system (brain, nerves, and spinal cord).
Belimumab may also be used for other purposes not listed in this medication guide.
Before you receive belimumab, tell your doctor if you have an active or chronic infection, a history of cancer, or a history of depression or mental illness.
Avoid being near people who have colds, the flu, or other contagious illnesses. Contact your doctor at once if you develop signs of infection. Do not receive a "live" vaccine within 30 days before or after you are treated with belimumab.
You may have thoughts about suicide while receiving belimumab, especially if you have a history of suicidal thoughts or actions. Report any new or worsening symptoms to your doctor, such as: depression, anxiety, mood or behavior changes, trouble sleeping, or thoughts about hurting yourself or others.
To make sure you can safely receive belimumab, tell your doctor if you have any of these other conditions:
an active or chronic infection;
a history of cancer; or
a history of depression or mental illness.
You may have thoughts about suicide while receiving belimumab, especially if you have a history of suicidal thoughts or actions.
Belimumab is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting. Belimumab must be given slowly, and the IV infusion can take about an hour to complete.
The first 3 doses of belimumab are given 2 weeks apart. Then the injections are given every 4 weeks. Your dosing schedule may be different. Follow your doctor's instructions.
Contact your doctor if you miss an appointment for your belimumab injection.
Avoid being near people who have colds, the flu, or other contagious illnesses.
new or worsening depression, anxiety, mood or behavior changes, trouble sleeping, or thoughts about hurting yourself or others;
chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling.
wheezing, chest tightness, trouble breathing; or
fever, chills, flu symptoms, night sweats, weight loss;
increased urination, pain or burning when you urinate;
cough with yellow or green mucus, stabbing chest pain, feeling short of breath;
swelling, pain, tenderness, or redness anywhere on your body; or
bloody diarrhea.
Less serious side effects may include:
nausea, diarrhea, stomach pain;
mild pain in your arms or legs; or
mild cold symptoms such as stuffy nose, sneezing, sore throat.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Systemic Lupus Erythematosus:
10 mg/kg as an intravenous infusion only, over a period of 1 hour, at 2 week intervals for the first 3 doses and at 4 week intervals thereafter.
Consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions.
Tell your doctor about all other medicines you use, especially:
cyclophosphamide (Cytoxan); or
drugs that weaken your immune system such as cancer medicine, steroids, and medicines to prevent rejection of a transplanted organ.
This list is not complete and other drugs may interact with belimumab. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: belimumab side effects (in more detail)
Monotrate may be available in the countries listed below.
Isosorbide Mononitrate is reported as an ingredient of Monotrate in the following countries:
International Drug Name Search
Coartem is a brand name of artemether/lumefantrine, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Coartem available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Coartem. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Isotic Azora may be available in the countries listed below.
Naphazoline hydrochloride (a derivative of Naphazoline) is reported as an ingredient of Isotic Azora in the following countries:
Pheniramine maleate (a derivative of Pheniramine) is reported as an ingredient of Isotic Azora in the following countries:
International Drug Name Search
Sefanid may be available in the countries listed below.
Cefadroxil is reported as an ingredient of Sefanid in the following countries:
International Drug Name Search
Neofomiral may be available in the countries listed below.
Fluconazole is reported as an ingredient of Neofomiral in the following countries:
International Drug Name Search
Magnecyl-koffein brus may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Magnecyl-koffein brus in the following countries:
Caffeine is reported as an ingredient of Magnecyl-koffein brus in the following countries:
International Drug Name Search
Morphinsulfat AbZ may be available in the countries listed below.
Morphine sulphate pentahydrate (a derivative of Morphine) is reported as an ingredient of Morphinsulfat AbZ in the following countries:
International Drug Name Search
Zaléplone may be available in the countries listed below.
Zaléplone (DCF) is known as Zaleplon in the US.
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
Dolostop may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Dolostop in the following countries:
Nimesulide is reported as an ingredient of Dolostop in the following countries:
Paracetamol is reported as an ingredient of Dolostop in the following countries:
International Drug Name Search
Magnesium + Vitamin E Ratiopharm may be available in the countries listed below.
Magnesium Oxide light (a derivative of Magnesium Oxide) is reported as an ingredient of Magnesium + Vitamin E Ratiopharm in the following countries:
Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Magnesium + Vitamin E Ratiopharm in the following countries:
International Drug Name Search
Recomox may be available in the countries listed below.
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Recomox in the following countries:
International Drug Name Search
Ora may be available in the countries listed below.
Epinephrine bitartrate (a derivative of Epinephrine) is reported as an ingredient of Ora in the following countries:
Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Ora in the following countries:
International Drug Name Search
DES-oh-nide
In the U.S.
In Canada
Available Dosage Forms:
Therapeutic Class: Corticosteroid, Strong
Pharmacologic Class: Adrenal Glucocorticoid
Desonide topical is used to help relieve redness, itching, swelling, or other discomfort caused by skin conditions (e.g., atopic dermatitis). desonide is a corticosteroid (cortisone-like medicine or steroid).
desonide is available only with your doctor's prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For desonide, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to desonide or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of desonide topical foam or gel in children 3 months of age and older. However, because of desonide's toxicity, it should be used with caution. Children may absorb large amounts through the skin, which can cause serious side effects. If your child is using desonide, follow your doctor's instructions very carefully. For the foam and gel forms, safety and efficacy have not been established in infants younger than 3 months of age. The safety and efficacy of desonide topical cream, lotion, and ointment have not been established in children and use is not recommended.
No information is available on the relationship of age to the effects of desonide topical cream, ointment, or lotion in geriatric patients.
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of desonide topical foam or gel in the elderly. However, elderly patients are more likely to have age-related kidney, liver, or heart problems, which may require caution in patients receiving desonide topical foam or gel.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | C | Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. |
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of desonide. Make sure you tell your doctor if you have any other medical problems, especially:
It is very important that you use desonide only as directed by your doctor. Do not use more of it, do not use it more often, and do not use it for a longer time than your doctor ordered. To do so may cause unwanted side effects or skin irritation.
desonide is for use on the skin only. Do not get it in your eyes, nose, mouth, or vagina. Do not use it on skin areas that have cuts, scrapes, or burns. If it does get on these areas, rinse it off right away with water.
desonide should only be used for skin conditions that your doctor is treating. Check with your doctor before using it for other conditions, especially if you think that a skin infection may be present. desonide should not be used to treat certain kinds of skin infections or conditions, such as severe burns.
Do not use the topical gel on the groin or underarms unless directed to do so by your doctor, and do not use this form for more than 4 weeks.
To use cream, gel, lotion, or ointment:
To use the foam:
The dose of desonide will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of desonide. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of desonide, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Store the foam can at room temperature, away from heat and direct light. Do not keep desonide inside a car where it could be exposed to extreme heat. Do not poke holes in the canister or throw it into a fire, even if the canister is empty.
It is very important that your doctor check the progress of you or your child at regular visits for any unwanted effects that may be caused by desonide.
If your or your child's symptoms do not improve within a few days, or if they become worse, check with your doctor.
Using too much of desonide or using it for a long time may increase your risk of having adrenal gland problems. The risk is greater for children and patients who use large amounts for a long time. Talk to your doctor right away if you or your child have more than one of these symptoms while you are using desonide: blurred vision; dizziness or fainting; a fast, irregular, or pounding heartbeat; increased thirst or urination; irritability; or unusual tiredness or weakness.
Stop using desonide and check with your doctor right away if you or your child have a skin rash, burning, stinging, swelling, or irritation on the skin.
Make sure your doctor knows that you are using desonide foam. You may need to stop using desonide several days before having surgery.
Do not use cosmetics or other skin care products on the treated areas.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: desonide Topical application side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Terbifin may be available in the countries listed below.
Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Terbifin in the following countries:
International Drug Name Search
Chloromycetin Ear Drops may be available in the countries listed below.
Chloramphenicol is reported as an ingredient of Chloromycetin Ear Drops in the following countries:
International Drug Name Search
Cefuroxim Axapharm may be available in the countries listed below.
Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Cefuroxim Axapharm in the following countries:
International Drug Name Search
Nabicortin may be available in the countries listed below.
Lovastatin is reported as an ingredient of Nabicortin in the following countries:
International Drug Name Search
Sandoz Anuzinc may be available in the countries listed below.
Zinc Sulfate monohydrate (a derivative of Zinc Sulfate) is reported as an ingredient of Sandoz Anuzinc in the following countries:
International Drug Name Search
In the US, Pediazole (erythromycin/sulfisoxazole systemic) is a member of the drug class miscellaneous antibiotics and is used to treat Otitis Media.
US matches:
Erythromycin is reported as an ingredient of Pediazole in the following countries:
Erythromycin ethylsuccinate (a derivative of Erythromycin) is reported as an ingredient of Pediazole in the following countries:
Erythromycin laurilsulfate (a derivative of Erythromycin) is reported as an ingredient of Pediazole in the following countries:
Sulfafurazole acetate (a derivative of Sulfafurazole) is reported as an ingredient of Pediazole in the following countries:
International Drug Name Search
Pevisone may be available in the countries listed below.
Econazole nitrate (a derivative of Econazole) is reported as an ingredient of Pevisone in the following countries:
Triamcinolone 16α,17α-acetonide (a derivative of Triamcinolone) is reported as an ingredient of Pevisone in the following countries:
International Drug Name Search
Theo-2 may be available in the countries listed below.
Theophylline is reported as an ingredient of Theo-2 in the following countries:
International Drug Name Search
Ivynosvin may be available in the countries listed below.
Xylometazoline is reported as an ingredient of Ivynosvin in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Ph. Eur.
0000122-99-6
C8-H10-O2
138
Antiseptic
Pharmaceutic aid: Preservative
Ethanol, 2-phenoxy-
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| PH | Pharmacopoeia Name |
| Ph. Eur. | European Pharmacopoeia |
Bioxilina may be available in the countries listed below.
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Bioxilina in the following countries:
International Drug Name Search
Afongan may be available in the countries listed below.
Omoconazole nitrate (a derivative of Omoconazole) is reported as an ingredient of Afongan in the following countries:
International Drug Name Search
Atermin may be available in the countries listed below.
Atenolol is reported as an ingredient of Atermin in the following countries:
International Drug Name Search
Pilison may be available in the countries listed below.
Fluocortolone 21-pivalate (a derivative of Fluocortolone) is reported as an ingredient of Pilison in the following countries:
International Drug Name Search
Analgiplus may be available in the countries listed below.
Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Analgiplus in the following countries:
Paracetamol is reported as an ingredient of Analgiplus in the following countries:
International Drug Name Search
Naproxennatrium Ratiopharm may be available in the countries listed below.
Naproxen sodium salt (a derivative of Naproxen) is reported as an ingredient of Naproxennatrium Ratiopharm in the following countries:
International Drug Name Search
Mecovit may be available in the countries listed below.
Mecobalamin is reported as an ingredient of Mecovit in the following countries:
International Drug Name Search
Benzatec may be available in the countries listed below.
Benzylpenicillin sodium (a derivative of Benzylpenicillin) is reported as an ingredient of Benzatec in the following countries:
International Drug Name Search
Fenilefrin may be available in the countries listed below.
Phenylephrine hydrochloride (a derivative of Phenylephrine) is reported as an ingredient of Fenilefrin in the following countries:
International Drug Name Search
A.N.B. Quinine Dihydrochloride may be available in the countries listed below.
Quinine hydrochloride (a derivative of Quinine) is reported as an ingredient of A.N.B. Quinine Dihydrochloride in the following countries:
International Drug Name Search
Metronidazol Biol may be available in the countries listed below.
Metronidazole is reported as an ingredient of Metronidazol Biol in the following countries:
International Drug Name Search
Rec.INN
N02AX05
0054340-58-8
C15-H23-N-O
233
Analgesic
Phenol, 3-(3-ethylhexahydro-1-methyl-1H-azepin-3-yl)-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| BANM | British Approved Name (Modified) |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Narutis may be available in the countries listed below.
Clopidogrel besilate (a derivative of Clopidogrel) is reported as an ingredient of Narutis in the following countries:
International Drug Name Search
Belosalic may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Belosalic in the following countries:
Betamethasone is reported as an ingredient of Belosalic in the following countries:
Betamethasone 17α,21-dipropionate (a derivative of Betamethasone) is reported as an ingredient of Belosalic in the following countries:
Mometasone 17-(2-furoate) (a derivative of Mometasone) is reported as an ingredient of Belosalic in the following countries:
Salicylic Acid is reported as an ingredient of Belosalic in the following countries:
International Drug Name Search
Kovel may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Calcium Chloride dihydrate (a derivative of Calcium Chloride) is reported as an ingredient of Kovel in the following countries:
Magnesium Chloride hexahydrate (a derivative of Magnesium Chloride) is reported as an ingredient of Kovel in the following countries:
International Drug Name Search
Ketoderm may be available in the countries listed below.
Ketoconazole is reported as an ingredient of Ketoderm in the following countries:
International Drug Name Search
Elcion may be available in the countries listed below.
Diazepam is reported as an ingredient of Elcion in the following countries:
International Drug Name Search
Evidon may be available in the countries listed below.
Tocopherol, α- is reported as an ingredient of Evidon in the following countries:
International Drug Name Search
Desal may be available in the countries listed below.
Furosemide is reported as an ingredient of Desal in the following countries:
International Drug Name Search
Muscalm D may be available in the countries listed below.
Tolperisone hydrochloride (a derivative of Tolperisone) is reported as an ingredient of Muscalm D in the following countries:
International Drug Name Search
Virtaz may be available in the countries listed below.
Aciclovir is reported as an ingredient of Virtaz in the following countries:
International Drug Name Search
Prisulfan may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfadiazine is reported as an ingredient of Prisulfan in the following countries:
Trimethoprim is reported as an ingredient of Prisulfan in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Monensin sodium salt (a derivative of Monensin) is reported as an ingredient of Moormans in the following countries:
International Drug Name Search
Heptodin may be available in the countries listed below.
Lamivudine is reported as an ingredient of Heptodin in the following countries:
International Drug Name Search
Aspirin Protect may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Aspirin Protect in the following countries:
International Drug Name Search
Vitamin E AL may be available in the countries listed below.
Tocopherol, α- is reported as an ingredient of Vitamin E AL in the following countries:
International Drug Name Search
Kosozole may be available in the countries listed below.
Albendazole is reported as an ingredient of Kosozole in the following countries:
International Drug Name Search
Mirtazapina Mylan may be available in the countries listed below.
Mirtazapine is reported as an ingredient of Mirtazapina Mylan in the following countries:
International Drug Name Search
Risperidon-neuraxpharm may be available in the countries listed below.
Risperidone is reported as an ingredient of Risperidon-neuraxpharm in the following countries:
International Drug Name Search
Class: Antihistamines
ATC Class: A04AD
CAS Number: 523-87-5
Brands: DMH, Dramamine, TripTone
Ethanolamine-derivative antihistamine containing a diphenhydramine moiety; antiemetic.b
Used principally in the prevention and treatment of nausea, vomiting, and/or vertigo associated with motion sickness, although scopolamine, promethazine, or meclizine may be more effective.b
Most effective when given prophylactically.b
Has been used for symptomatic treatment (e.g., nausea, vomiting, vertigo) of Ménière’s disease† and other vestibular disturbances†.b
May be less effective than phenothiazines in controlling nausea and vomiting not related to vestibular stimulation.b
Although a histamine antagonist, use in allergic conditions† has not been evaluated.b
Administer orally or by IM or IV injection.a b
Each 50 mg must be diluted with 10 mL of 0.9% sodium chloride injection.b
Inject IV slowly over a period of 2 minutes.b
For prevention, take 30 minutes before exposure to motion.b
Children <2 Years of Age: Give only under the direction of a clinician.100 101
Children 2 to <6 Years of Age: 12.5–25 mg every 6–8 hours, not to exceed 75 mg in 24 hours, or as directed by a clinician.100 101 102
Children 6 to <12 Years of Age: 25–50 mg every 6–8 hours, not to exceed 150 mg in 24 hours, or as directed by a clinician.100 101 102
Children ≥12 Years of Age: Usually, 50–100 mg every 4–6 hours, not to exceed 400 mg in 24 hours, or as directed by a clinician.100 101 102
Children: Alternatively, 1.25 mg/kg or 37.5 mg/m2 4 times daily, up to a maximum of 300 mg daily.b
Children: 1.25 mg/kg or 37.5 mg/m2 4 times daily, up to a maximum of 300 mg daily.b
Not established for children.b
For prevention, take 30 minutes before exposure to motion.b
Usually 50–100 mg every 4–6 hours, not to exceed 400 mg in 24 hours, or as directed by a clinician.100 101 102
50–100 mg every 4–6 hours, not to exceed 400 mg in 24 hours, or as directed by a clinician.b
50–100 mg every 4–6 hours, not to exceed 400 mg in 24 hours, or as directed by a clinician.b
25–50 mg has been given 3 times daily.b
50 mg.b
Children 2 to <6 Years of Age: Maximum 75 mg in 24 hours, or as directed by a clinician.100 101 102
Children 6 to <12 Years of Age: Maximum 150 mg in 24 hours, or as directed by a clinician.100 101 102
Children ≥12 Years of Age: Maximum 400 mg in 24 hours, or as directed by a clinician.100 101 102
Children: Alternatively, maximum 300 mg daily when given as 1.25 mg/kg or 37.5 mg/m2.b
300 mg daily.b
Maximum 400 mg in 24 hours, or as directed by a clinician.100 101 102
Maximum 400 mg in 24 hours, or as directed by a clinician.b
Maximum 400 mg in 24 hours, or as directed by a clinician.b
No specific dosage recommendations for hepatic impairment.a b
No specific dosage recommendations for renal impairment.a b
No specific geriatric dosage recommendations.a
Dimenhydrinate contains 53–55.5% diphenhydramine.a b Concomitant use with other preparations containing diphenhydramine, including oral and topical preparations, is contraindicated.
Known hypersensitivity to dimenhydrinate, other antihistamines with similar chemical structure, or any ingredient in the formulation.
Patients with glaucoma, respiratory conditions (e.g., emphysema, chronic bronchitis), or difficulty urinating due to prostatic hypertrophy should consult a clinician before initiating therapy with dimenhydrinate.a b
Use with caution in patients with increased IOP, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, bladder-neck obstruction, symptomatic prostatic hypertrophy, active or a history of lower respiratory disease (e.g., bronchial asthma), hyperthyroidism, or cardiovascular disease (e.g., hypertension).a b
Risk of marked drowsiness.c Among first generation antihistamines, ethanolamines (e.g., dimenhydrinate) considered the most sedating.c
Performance of activities requiring mental alertness or physical coordination may be impaired.a b
Concurrent use of other CNS depressants may cause additive or potentiated CNS depression.a
Dimenhydrinate contains 53–55.5% diphenhydramine.a b Risk of diphenhydramine toxicity. (See Pediatric Use under Cautions.) Do not use more often than directed for any condition or use concomitantly with other diphenhydramine-containing preparations, including oral and topical preparations.
Dramamine chewable tablets contain tartrazine (FD&C yellow No. 5), which may cause allergic reactions including bronchial asthma in susceptible individuals.a b Incidence of tartrazine sensitivity is low, but it frequently occurs in patients who are sensitive to aspirin.b
Consider anticholinergic effects in patients with conditions aggravated by anticholinergic therapy (e.g., angle-closure glaucoma, enlargement of the prostate gland).b (See Concomitant Diseases under Cautions.)
Symptoms of ototoxicity may be masked by dimenhydrinate; administer with caution in patients receiving known ototoxic drugs and closely monitor.b
Use with caution in seizure disorders.b
Category C.pdh
Distributed into milk.b Discontinue nursing or the drug.b
Do not use in children <2 years of age unless directed by a clinician.a
Risk of diminished mental alertness. Risk of excitation in young pediatric patients.b
Risk of diphenhydramine toxicity (e.g., dilated pupils, flushed face, hallucinations, ataxic gait, urinary retention) when used concomitantly with other diphenhydramine-containing preparations, including oral and topical preparations. (See Diphenhydramine Toxicity under Cautions.)
Drowsiness, headache, blurred vision, tinnitus, dryness of the mouth and respiratory passages, incoordination, palpitation, dizziness, hypotension.b
Paradoxical CNS stimulation in pediatric patients and occasionally in adults.b
With IM injection: Pain at the injection site.b
Because dimenhydrinate contains diphenhydramine, the possibility of other diphenhydramine-related adverse effects should also be considered.b
Although dimenhydrinate has been reported to induce hepatic microsomal enzymes in animals, there is no clinical evidence that it influences the metabolism of other drugs in humans.b
Drug | Interaction | Comments |
|---|---|---|
Anticholinergic drugs | Anticholinergic effects may be potentiatedb | |
Antidepressants, tricyclic | Anticholinergic effects may be potentiatedb | |
CNS depressants | May enhance the effects of other CNS depressants, including alcoholb | Use concomitantly with cautionb |
Ototoxic drugs | May mask the early manifestations of ototoxicityb | Use concomitantly with caution and closely monitorb |
Well absorbed after oral or parenteral administration.b
IV injection: Antiemetic effects occur almost immediately.b
Oral administration: Antiemetic effects within 15–30 minutes.b
IM injection: Antiemetic effects within 20–30 minutes.b
3–6 hours.b
Probably widely distributed into body tissues.b
Crosses the placenta.b
Small amounts are distributed into milk.b
Metabolized by the liver.b
Excreted in urine.b
Well-closed containers at room temperature.b d
Tight containers.b d Avoid freezing.b
Well-closed containers at room temperature.b d
Avoid freezing.b
For information on systemic interactions resulting from concomitant use, see Interactions.
Compatible |
|---|
Dextran 6% in dextrose 5% |
Dextran 6% in sodium chloride 0.9% |
Dextrose–Ringer’s injection combinations |
Dextrose–Ringer’s injection, lactated, combinations |
Dextrose–saline combinations |
Dextrose 5% in sodium chloride 0.9% |
Dextrose 2.5, 5, or 10% in water |
Fructose 10% in sodium chloride 0.9% |
Fructose 10% in water |
Invert sugar 5 and 10% in sodium chloride 0.9% |
Invert sugar 5 and 10% in water |
Ionosol products |
Ringer’s injection |
Ringer’s injection, lactated |
Sodium chloride 0.45 or 0.9% |
Sodium lactate (1/6) M |
Compatible |
|---|
Amikacin sulfate |
Calcium gluconate |
Chloramphenicol sodium succinate |
Heparin sodium |
Hydroxyzine HCl |
Norepinephrine bitartrate |
Penicillin G potassium |
Pentobarbital sodium |
Phenobarbital sodium |
Potassium chloride |
Prochlorperazine edisylate |
Vancomycin HCl |
Vitamin B complex with C |
Incompatible |
Thiopental sodium |
Variable |
Aminophylline |
Ammonium chloride |
Amobarbital sodium |
Hydrocortisone sodium succinate |
Compatible |
|---|
Acyclovir sodium |
Ciprofloxacin |
Fluconazole |
Metronidazole |
Pantoprazole sodium |
Most actions are believed to result principally from its diphenhydramine moiety.b
Has CNS depressant, anticholinergic, antiemetic, antihistaminic, and local anesthetic effects.b
Has been shown to inhibit vestibular stimulation, acting first on the otolith system, and in larger doses on the semicircular canals.b
Inhibits acetylcholine; this may be its primary mechanism of action, since cholinergic stimulation in the vestibular and reticular systems may be responsible for the nausea and vomiting of motion sickness.b
Tolerance to CNS depressant effects usually occurs after a few days of treatment, and some decrease in antiemetic effectiveness may be noted after prolonged use.b
Potential for drug to impair mental alertness or physical coordination; avoid driving or operating machinery until effects on individual are known.a b
Importance of warning patients with tartrazine or aspirin sensitivity that Dramamine chewable tablets contain the dye tartrazine (FD&C yellow No. 5), which may cause allergic reactions including bronchial asthma.a b .
Importance of not using multiple diphenhydramine-containing preparations (either oral or topical) simultaneously because of risk of toxicity. (See Diphenhydramine Toxicity under Cautions.)
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Solution | 12.5 mg/5 mL* | DMH Syrup | Alra |
Dramamine Children’s (with methylparaben) | Pfizer | |||
Tablets | 50 mg* | Dramamine (scored) | Pfizer | |
Tablets, chewable | 50 mg | Dramamine Children’s (with sorbitol and tartrazine; scored) | Pfizer | |
Tablets, film-coated | 50 mg | TripTone Caplets (scored) | Del | |
Parenteral | Injection | 50 mg/mL* | Dimenhydrinate Injection (with propylene glycol and benzyl alcohol) | Abraxis |
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions August 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
Only references cited for selected revisions after 1984 are available electronically.
100. Food and Drug Administration. Antiemetic drug products for over-the-counter human use; final monograph. Fed Regist. 1987; 52:15886-93.
101. Richardson-Vicks Inc. Dramamine Liquid, Dramamine tablets, and Dramamine Chewable tablets prescribing information. In: Huff BB, ed. Physicians’ desk reference. 42nd ed. Oradell, NJ: Medical Economics Company Inc; 1988(Suppl A):A30-1.
102. Food and Drug Administration. Over-the-counter drug products; final monographs for antiemetic, antitussive, bronchodilator, and antihelmintic drug products; updating and technical changes Fed Regist. 1988; 53:35808-10. (21 CFR Parts 336, 341, and 357 [Docket No. 88N-0070])
556. Food and Drug Administration. Labeling of diphenhydramine-containing drug products for over-the-counter human use. 21 CFR Parts 336, 338, 341, 348. Proposed rule. [Docket No. 97N-0128] Fed Regist. 1997; 62:45767-74.
557. Chan CYJ, Wallander KA. Diphenhydramine toxicity in three children with varicella- zoster infection. DICP. 1991; 25:130-2. [IDIS 278321] [PubMed 2058184]
575. McGann KP, Pribanich S, Graham JA et al. Diphenhydramine toxicity in a child with varicella: a case report. J Fam Pract. 1992; 35:210,213-4. [PubMed 1645115]
576. Woodward GA, Baldassano RN. Topical diphenhydramine toxicity in a five year old with varicella. Pediatr Emerg Care. 1988; 4:18-20. [PubMed 3362727]
672. Food and Drug Administration. Labeling of diphenhydramine-containing drug products for over-the-counter human use. 21 CFR Parts 336, 338, 341, 348. Final rule. [Docket No. 97N-0128] Fed Regist. 2002; 67:72555-9.
a. Pharmacia Consumer Healthcare. Dramamine (dimenhydrinate) Original Formula and Chewable tablets prescribing information. Peapack, NJ: 2004 Apr.
b. AHFS drug information 2004. McEvoy GK, ed. Dimenhydrinate. American Society of Health-System Pharmacists; 2004: 2786-7.
c. AHFS drug information 2004. McEvoy GK, ed. Antihistamines general statement. American Society of Health-System Pharmacists; 2004:2-9.
d. The United States pharmacopeia, 27th rev, and The national formulary, 22nd ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 2004:10,628-31.
pdh. Schilling McCann JA, Publisher. Pharmacists drug handbook. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins and American Society of Health-System Pharmacists; 2003.
HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:529-35.
